Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTS NYSE:MTNB NASDAQ:OBSV NASDAQ:TAOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSBiophytis$13.37$8.05▼$168.80$2.89M1.057,291 shs18,500 shsMTNBMatinas Biopharma$1.84-10.0%$1.19$0.47▼$4.49$9.34M1.32437,585 shs43,692 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs18,171 shsTAOXSynaptogenix$5.82-11.1%$0.00$1.84▼$11.98$20.31M1.87423,552 shs424,155 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSBiophytis0.00%0.00%0.00%0.00%0.00%MTNBMatinas Biopharma+3.03%+17.24%+133.41%+151.23%+998.55%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%TAOXSynaptogenix-5.35%+1.55%-4.52%+654,999,900.00%+654,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTSBiophytisN/AN/AN/AN/AN/AN/AN/AN/AMTNBMatinas Biopharma0.6437 of 5 stars0.05.00.00.01.10.00.6OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ATAOXSynaptogenixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSBiophytis 0.00N/AN/AN/AMTNBMatinas Biopharma 2.00HoldN/AN/AOBSVObsEva 0.00N/AN/AN/ATAOXSynaptogenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSBiophytisN/AN/AN/AN/A($17.29) per shareN/AMTNBMatinas BiopharmaN/AN/AN/AN/A$4.43 per shareN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ATAOXSynaptogenixN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSBiophytis-$18.43MN/A0.00N/AN/AN/AN/AN/AN/AMTNBMatinas Biopharma-$22.94M-$3.89N/A∞N/AN/A-123.06%-94.28%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ATAOXSynaptogenix-$12.77M-$20.16N/A∞N/AN/A-277.76%-150.79%N/ALatest BPTS, TAOX, MTNB, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025TAOXSynaptogenixN/A-$11.26N/A-$11.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSBiophytisN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ATAOXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSBiophytisN/A0.720.72MTNBMatinas BiopharmaN/A5.535.53OBSVObsEvaN/A0.610.61TAOXSynaptogenixN/A20.5220.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSBiophytis0.05%MTNBMatinas Biopharma11.77%OBSVObsEva17.52%TAOXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipBPTSBiophytis3.70%MTNBMatinas Biopharma4.60%OBSVObsEva14.40%TAOXSynaptogenix2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTSBiophytis22351,000338,000Not OptionableMTNBMatinas Biopharma305.09 million4.60 millionN/AOBSVObsEva5077.97 million66.74 millionNot OptionableTAOXSynaptogenix43.49 million3.39 millionN/ABPTS, TAOX, MTNB, and OBSV HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to SellAugust 19, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTS, TAOX, MTNB, and OBSV Company DescriptionsBiophytis NASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Matinas Biopharma NYSE:MTNB$1.84 -0.21 (-10.05%) Closing price 03:58 PM EasternExtended Trading$1.84 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Synaptogenix NASDAQ:TAOX$5.82 -0.73 (-11.15%) As of 04:00 PM EasternSynaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big Chevron Stock Outlook: Dividend Growth Meets Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access